The Bioprojet company was founded in 1982 under the impetus of Jeanne-Marie Lecomte and Jean-Charles Schwartz, doctors of pharmacy and sciences. From very different backgrounds, Jeanne-Marie Lecomte made her career in the pharmaceutical industry, whereas Jean-Charles Schwartz continued down the university pathway. They decided to bring together academic research and industrial pharmaceutical development, an uncommon practice at that time. With Bioprojet, they are following an objective based on novel fundamental research work in order to design and develop drugs destined to be forerunners in new therapeutic groups. To achieve this ambition, Bioprojet has partnered with Inserm, where Jean-Charles Schwartz leads a research unit, and with various Medicinal Chemistry university laboratories.
Today, Bioprojet is divided into two entities, bringing together 87 employees in charge of drug development and marketing:
- Bioprojet PHARMA, created in 1992, brings together 42 employees in charge of drug development and marketing.
- Bioprojet BIOTECH, created in 2001, brings together 45 employees managing the Group’s R&D. There are four units: biochemistry / molecular biology, therapeutic chemistry, pharmacology and pharmacokinetics.